Trial Profile
A Phase I/II Study Evaluating the Safety and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Pancreas Cancer During Surgical Procedures
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs ABY 029 (Primary) ; Panitumumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Diagnostic use
- 22 Nov 2023 Status changed to recruiting.
- 31 May 2023 Planned End Date changed from 1 Feb 2023 to 1 Sep 2027.
- 31 May 2023 Planned primary completion date changed from 1 Feb 2023 to 1 Mar 2026.